Stem definition | Drug id | CAS RN |
---|---|---|
beta-lactamase inhibitors | 5253 | 1360457-46-0 |
Dose | Unit | Route |
---|---|---|
3 | g | P |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.29 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.94 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.67 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.34 hours | Lombardo F, Berellini G, Obach RS |
S (Water solubility) | 5.26 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 29, 2017 | FDA | REMPEX PHARMS INC |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | J01DH52 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D065093 | beta-Lactamase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
FDA MoA | N0000000202 | beta Lactamase Inhibitors |
FDA EPC | N0000175930 | beta Lactamase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Escherichia coli urinary tract infection | indication | 301011002 | |
Urinary tract infection caused by Klebsiella | indication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.76 | acidic |
pKa2 | 9.79 | acidic |
pKa3 | 13.85 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 10183034 | Aug. 8, 2031 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX |
1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 10561675 | Aug. 8, 2031 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX |
1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 11007206 | Aug. 8, 2031 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED |
1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 9694025 | Aug. 8, 2031 | TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS |
1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 11376237 | April 6, 2039 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | Aug. 29, 2022 | NEW CHEMICAL ENTITY |
1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | Aug. 29, 2027 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-lactamase | Enzyme | Ki | 7.25 | CHEMBL |
ID | Source |
---|---|
1C75676F8V | UNII |
4036930 | VANDF |
C4519317 | UMLSCUI |
4D6 | PDB_CHEM_ID |
CHEMBL3317857 | ChEMBL_ID |
56649692 | PUBCHEM_CID |
DB12107 | DRUGBANK_ID |
D10998 | KEGG_DRUG |
10182 | INN_ID |
C000599945 | MESH_SUPPLEMENTAL_RECORD_UI |
10871 | IUPHAR_LIGAND_ID |
33058 | MMSL |
d08644 | MMSL |
017323 | NDDF |
737669009 | SNOMEDCT_US |
1945213 | RXNORM |
C000626994 | MESH_SUPPLEMENTAL_RECORD_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
VABOMERE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70842-120 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 28 sections |
VABOMERE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70842-120 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 28 sections |